3 Cardiac and Multi Speciality Hospital Group, Radiology and Pathology Provider and Chronic Care Drug Maker Stocks With a Strong Future Roadmap: Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences
- November 4, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences: ROE of 10.3% to 17.8% and FY22 to FY26 revenue CAGR of 14.8% to 22.9%. Prices as of 3 Nov 2026.
Quick Answer
The three hospital, diagnostics and chronic drug stocks to watch are Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences. Their return on equity ranges from 10.3% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.8% to 22.9%. Narayana Hrudayalaya has the highest return on equity at 17.8%, while Eris Lifesciences has the fastest revenue growth at 22.9% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Hospital, diagnostics and chronic drug stocks give investors a way to track businesses that sit close to everyday demand in India. Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences cover a hospital group, a diagnostics services provider and a chronic therapies drug maker.
This list covers three hospital, diagnostics and chronic drug stocks with complete current figures: Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital, Diagnostics and Chronic Drug Stocks?
Hospital, diagnostics and chronic drug stocks are listed companies that run affordable cardiac and multi-speciality hospitals, provide radiology and pathology services through government hospital partnerships and own centres, and sell branded medicines in cardiac, diabetes and gastro-intestinal care. Their earnings depend on patient volumes, test volumes and prescription demand.
Hospital, Diagnostics and Chronic Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Narayana Hrudayalaya | 1,870.6 | 35,603 | 43.6 | 59.6 | 17.8 | 1.29 |
| Krsnaa Diagnostics | 485.8 | 1,615 | 16.6 | 58.4 | 10.3 | 0.55 |
| Eris Lifesciences | 1,177.7 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital, diagnostics and chronic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Hospital, Diagnostics and Chronic Drug Stocks Have a Strong Roadmap in India?
Hospital, diagnostics and chronic drug stocks have a strong roadmap in India because rising healthcare spending, wider insurance cover and growing demand for tests and chronic care medicines keep widening the market for these healthcare companies.
- Hospitals. Patients seek affordable specialised care.
- Diagnostics. Public partnerships bring tests to more people.
- Chronic care drugs. Long term therapies support steady sales.
Why Narayana Hrudayalaya Features Among These Hospital, Diagnostics and Chronic Drug Stocks
Among the hospital, diagnostics and chronic drug stocks on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.
The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.
Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.
Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.
Why Krsnaa Diagnostics Features Among These Hospital, Diagnostics and Chronic Drug Stocks
Among the care delivery and pharma shares on this list, Krsnaa Diagnostics provides radiology and pathology services through partnerships with government hospitals and through its own diagnostic centres across many states.
Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%.
In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4.
Roadmap: The company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.
What to watch: Track new contract wins, test volumes and the rollout of advanced imaging.
Why Eris Lifesciences Features Among These Hospital, Diagnostics and Chronic Drug Stocks
Among the three companies on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.
Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Narayana Hrudayalaya vs Krsnaa Diagnostics vs Eris Lifesciences on Key Financials
The table below sets the three hospital, diagnostics and chronic drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Narayana Hrudayalaya | 3,736 | 7,996 | 21.0% | 810 | 10.1% |
| Krsnaa Diagnostics | 470 | 816 | 14.8% | 101 | 12.4% |
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya has the largest FY26 revenue at Rs 7,996 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with hospital, diagnostics and chronic drug stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Hospital, Diagnostics and Chronic Drug Stocks
Every theme carries risks that deserve a check before any decision. For these hospital, diagnostics and chronic drug stocks, the main points are: Long-term care delivery and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Test volumes. Footfall and test mix can vary with seasons.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hospital, diagnostics and chronic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hospital, Diagnostics and Chronic Drug Stocks
Hospital, diagnostics and chronic drug stocks work best when investors track growth, valuation and return on equity side by side. Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences each have a clear plan to grow. Based on the 3 November 2026 close, Narayana Hrudayalaya trades at Rs 1,870.6, Krsnaa Diagnostics at Rs 485.8 and Eris Lifesciences at Rs 1,177.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these hospital, diagnostics and chronic drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track hospital, diagnostics and chronic drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hospital, diagnostics and chronic drug stocks?
Ans. Hospital, diagnostics and chronic drug stocks are listed companies that run affordable cardiac and multi-speciality hospitals, provide radiology and pathology services through government hospital partnerships and own centres, and sell branded medicines in cardiac, diabetes and gastro-intestinal care. Their earnings depend on patient volumes, test volumes and prescription demand. This list looks at three of them, Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which hospital, diagnostics and chronic drug stocks are covered in this list?
Ans. This list covers Narayana Hrudayalaya, Krsnaa Diagnostics and Eris Lifesciences. Based on the 3 November 2026 close, Narayana Hrudayalaya traded at Rs 1,870.6, Krsnaa Diagnostics at Rs 485.8 and Eris Lifesciences at Rs 1,177.7. Their return on equity ranges from 10.3% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.8% to 22.9%.
Why do hospital, diagnostics and chronic drug stocks have a strong future roadmap in India?
Ans. Hospital, diagnostics and chronic drug stocks have a strong roadmap in India because rising healthcare spending, wider insurance cover and growing demand for tests and chronic care medicines keep widening the market for these healthcare companies. The main drivers are as follows. Hospitals. Patients seek affordable specialised care. Diagnostics. Public partnerships bring tests to more people. Chronic care drugs. Long term therapies support steady sales. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Narayana Hrudayalaya performed financially?
Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
How has Krsnaa Diagnostics performed financially?
Ans. Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What risks should investors check before buying hospital, diagnostics and chronic drug stocks?
Ans. Investors should check a few risks before buying hospital, diagnostics and chronic drug stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Test volumes. Footfall and test mix can vary with seasons. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hospital, diagnostics and chronic drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
